4th European Workshop on Protein **Aggregation and Immunogenicity**



DEADLINE abstract submission for a poster presentation 30 December 2018

28 to 29 January 2019 Salzburg, Austria

Course no. 6766



Target group

The course is designed for all scientists involved in the development and manufacture of therapeutic proteins, working in Pharmaceutical and Biopharmaceutical Industry or at suppliers of analytical equipment or at service companies contributing, e.g. to analytical characterization of therapeutic protein drug products.



Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik e.V. Gemeinnütziger wissenschaftlicher Verein International Association for Pharmaceutical Technology

Biotechnology

A seminar organised by the APV focus group Pharmaceutical Biotechnology

Goals of the seminar

Therapeutic protein candidates play an important role in the pipelines of pharmaceutical companies and the marketplace despite of specific analytical, formulation and safety challenges. This conference, held under the auspices of APV (www.apv-mainz.de), will focus on issues of protein aggregation and its impact on the immunogenicity of therapeutic proteins. Gathering opinion leaders from academia, industry and regulatory authorities, the conference will cover a broad range of topics from what causes aggregation of therapeutic proteins in formulation and processing, analytical methods of detecting aggregates, the utility of in vitro and animal models in assessing immunogenicity, to the clinical aspects of therapeutic protein immunogenicity. Options to control aggregates and particles in therapeutic protein formulation and processing will also be discussed from a hands-on experience. The seminar offers the opportunity to students to present their latest results in poster format, and the display of advanced analytical technology to suppliers in an industrial exhibition.

Organising committee

- Vasco Filipe, Sanofi (Chair)
- Karoline Bechtold-Peters, Novartis (Chair)
- John Carpenter, University of Colorado
- Wim Jiskoot, Leiden University
- Tarik Khan, Roche
- Hanns-Christian Mahler, Lonza
- Roman Mathaes, Lonza
- Tim Menzen, Coriolis Pharma
- Linda Narhi, Amgen

Abstract submission



Participants get the chance to submit abstracts for a poster presentation during the conference.

The abstract should be prepared using Microsoft Word as two A4 pages typed in Times New Roman, font size 12.

Please submit your abstracts by e-mail to Valentina Marinkova, marinkova@apv-mainz.de. Deadline for abstract submission: 30 December 2018.

Exhibition and sponsoring

For exhibition and sponsoring opportunities please get in touch with the APV headquarters, Valentina Marinkova, **marinkova@apv-mainz.de**.

Programme

Monday, 28 January 2019

10:00-18:00 h

Welcome address Vasco Filipe, Sanofi, Paris, France Karoline Bechtold-Peters, Novartis, Basel, Switzerland

Immunogenicity risk of biological medicinal products – A regulator's view Amy Rosenberg, FDA, United States

Session 1: Immunogenicity of therapeutic proteins

Overview about immunogenicity and state of the art assessments Daniel Kramer, Sanofi, Frankfurt/Main, Germany

Clinical consequences of immunogenicity Gertjan Wolbink, Sanquin, Amsterdam, Netherlands

T-cell assays confirm immunogenicity of tungsteninduced erythropoietin aggregates associated with pure red cell aplasia Michael Kammüller, Novartis, Basel, Switzerland

Lab-on-chip immune organoids that recapitulate germinal centers Ankur Singh – Cornell University, United States

Effect of aggregate size on monoclonal antibody immunogenicity in a mouse model Wim Jiskoot, Leiden University/Coriolis, Netherlands

In silico prediction Anne De Groot, EpiVax, Inc., USA

Update on the Cross-lab Study about Protein Aggregation and Biological Consequences Tim Menzen, Coriolis, Martinsried, Germany

Disscussion

Poster session and wine

Networking dinner

4th European Workshop on Protein Aggregation and Immunogenicity

Programme

Tuesday, 29 January 2019

08:30-16:30 h

Session 2: Protein aggregation and formulation

From Assays to Benefit/Risk Assessment: A European Assessors Perspective on Unwanted Immunogenicity of Biologicals Guenter Waxenecker, AGES, Austria

A nanoparticle platform as highly controlled surface stress assay for antibody aggregation Paolo Arosio, ETH Zurich, Zurich, Switzerland

Critical review of characterization methods for protein aggregates Andrea Hawe, Coriolis, Martinsried, Germany

Effects of end-user handling on particle formation in therapeutic protein products John F. Carpenter, University of Colorado, School of Pharmacy, Aurora, United States

Specification settings for protein aggregates industrial perspective Anja Matter, Lonza, Basel, Switzerland

Chemical degradation of Proteins Christian Schöneich, Kansas University, USA

Protein-Device compatibility and integration Ahmed Basheer, Lonza, Basel, Switzerland

Surfactants, Molecular Properties, Primary Packaging, and the Formation of Protein-Silicone Oil Particles Tarik Khan, F. Hoffmann-La Roche Ltd., Basel, Switzerland

Biosimilars and protein aggregation Andreas Seidl, Hexal, Oberhaching, Germany

Moderators of the workshop



Karoline Bechtold-Peters is

pharmacist and holds a Doctor's degree from the University of Munich as well as a degree as "Fachapotheker" for Pharmaceutical Technology.

She began her industrial career in 1994 at Boehringer Ingelheim in

Ingelheim developing solid dosage forms with the focus on powders for inhalation (e.g. Spiriva Inhalet). In 2000 she changed from the small molecule world to biopharmaceuticals building up Formulation Development at Boehringer Ingelheim's Biberach site. In 2003 Karoline took over the responsibility for global clinical supplies, aseptic process development and process transfer within Boehringer Ingelheim Biopharmaceuticals. Beginning of 2011, Karoline joined F. Hoffmann-La Roche AG in Basel, Switzerland, where she was appointed Head of Clinical Manufacturing, Process Science and Business Excellence. In September 2016 she moved finally to Novartis in Basel, Switzerland, as Senior Strategy & Technology Leader Pharmaceutics, Global Drug Development / TRD (Biologics) and is part of the BioFuture team. Karoline is active in various associations (American Association of Pharmaceutical Scientists AAPS, Parenteral Drug Association PDA and International Association for Pharmaceutical Technology APV) and contributes frequently to conferences in the EU as well as in the US.



Vasco Filipe is a Biological Engineer and obtained a Ph.D. degree in Pharmaceutical Sciences from the Utrecht University (The Netherlands) in 2011.

His thesis focused on the physicochemical characteristics, stability

in biological fluids and immunogenicity of monoclonal antibody aggregates. After a post-doc in 2012 on a similar topic, he then joined Adocia in 2013 (Lyon, France), where he worked as the Project Leader for monoclonal antibodies.

In 2015 he joined Sanofi in Paris (France), where he works as a Unit Head in the department of Pharmaceutical Development of Biologics.



Location Austria Trend Comfort Hotel Salzburg West Bundesstraße 4 5073 Salzburg-Wals Austria phone 0043 662 8581 0	Registration feeEarly bird until 25 November 2018Industry1390 EURAuthority/University695 EURStudents*150 EUR(free of VAT according to § 4,22 UStG)	Registration APV-Headquarters Kurfürstenstraße 59 55118 Mainz/Germany phone 0049 6131 97 69 0 fax 0049 6131 97 69 69 Eemail apv@apv-mainz.de	Hotel reservation Austria Trend Comfort Hotel Salzburg West Bundesstraße 4 5073 Salzburg-Wals Austria phone 0043 662 8581 0 mail salzburg.west@austria-trend.at
Date	Rate from 26 November 2018Industry1490 EURAuthority/University745 EURStudents*178 EUR	web www.apv-mainz.de You will receive a confirmation of your registration with the invoice.	Participants should make their own hotel reservation referring to the APV seminar.
Course No. 6766 from 28 January 2019 10:00 h to 29 January 2019 16:30 h	7 2019 10:00 h 019 16:30 h Coffee breaks, luncheons, dinner and electronic proceedings included. I herewith repealable authorise th organizers to use my e-mail addre to send me relevant material including current programme	including current programme information. My acceptance can be	Deadline for special conference rate: 26 December 2018. Special rate: Single room incl. breakfast from 95,00 € per night.
	students available; written evidence must be submitted.		Mainz, September 2018

4th European Workshop on Protein Aggregation and Immunogenicity, 28 to 29 January 2019, Salzburg, Austria, Course no.: 6766

Company name *

Location *

Zip-code *

Phone *

Department *

E-mail address participant *

Street/no. or P.O. box *

Title, first name, last name *

Registration

As soon as you have found a seminar of your interest, it is very easy to register for it via fax, e-mail or online. We will process your registration promptly and certainly are available for any questions that may arise.

Registration confirmation

After your registration was successfully processed, you will receive a confirmation.

Before the event

A few days before the event starts, you will receive important information about the seminar, such as time, date, addresses etc.

After the event

You will receive a certificate confirming your participation. Furthermore, we would like to ask you to fill-in our evaluation sheet to make sure we get better every time.

Follow-up

After the event, we are open to receive any suggestions and critique that might arise during the seminar and will certainly help you with further questions you may have.

questions you may have.				
pay via invoice pay via credit card (fill in below) AMEX Visa	Order no. or billing address *			
Card holder	Date	Signature		
Card no.	* Mandatory Arbeitsgemeinschaft für Pharmazeutis	che	AP\/-Ges	chäftsstelle
Valid until	Verfahrenstechnik e.V. Gemeinnütziger wissenschaftlicher Verein		Kurfürstenstraße 59 55118 Mainz/Germany	
CCV code	International Association for Pharmaceution Technology WWW.apv-mainz.de	cal	phone fax e-mail web	0049 6131 97 69 0 0049 6131 97 69 69 apv@apv-mainz.de www.apv-mainz.de
	-			